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Abstract
Background: Patients with Echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase
(ALK) positive lung cancer are sensitive to ALK-kinase inhibitors. TAE684 is a potent second generation ALK inhibitor
that overcomes Crizotinib resistance. Radiotherapy is an integral therapeutic component of locally advanced lung
cancer. Therefore, we sought to investigate the effects of combined radiotherapy and ALK-inhibition via TAE684 in
ALK-positive vs. wild type lung cancer cells.
Methods: Human non-small cell lung cancer (NSCLC) cell lines harboring wild-type ALK (A549), EML4-ALK translocation
(H3122) and murine Lewis Lung Cancer (LLC) cells were investigated. Cells were irradiated with 1–4 Gy X-Rays (320 keV)
and carbon ions (Spread-out Bragg Peak, SOBP (245.4–257.0 MeV/u)) at Heidelberg Ion Therapy center. TAE684 was
administered at the dose range 0–100 nM. Clonogenic survival, proliferation and apoptosis via caspase 3/7 expression
level were assessed in all three cell lines using time-lapse live microscopy.
Results: TAE684 inhibited the proliferation of H3122 cells in a dose-dependent manner with a half maximal inhibitory
concentration (IC50) of ~ 8.2 nM. However, A549 and LLC cells were relatively resistant to TAE684 and IC50 was
not reached at concentrations tested (up to 100 nM) in proliferation assay. The antiproliferative effect of TAE684
was augmented by radiotherapy in H3122 cells. TAE684 significantly sensitized H3122 cells to particle therapy
with carbon ions (sensitizer enhancement ratio ~1.61, p < 0.05). Caspase 3/7 activity was evidently enhanced after
combination therapy in H3122 cells.
Conclusions: This is the first report demonstrating synergistic effects of combined TAE684 and radiotherapy in
EML4-ALK positive lung cancer cells. In addition to conventional photon radiotherapy, ALK-inhibition also enhanced
the effects of particle irradiation using carbon ions. Our data indicate beneficial effects of combined ALK-inhibition and
radiotherapy in treatment of this distinct subpopulation of NSCLC that warrant further evaluation.
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Background
Lung cancer is the leading cause of cancer mortality
worldwide, and NSCLC comprises about 80% of lung
cancer cases. Most patients are diagnosed with non-
resectable diseases and approximately 1/3 present with
locally advanced diseases (stage III) i.e., the tumor may
exceed the structures of the lung itself and/or have
spread to ipsilateral mediastinal and/or subcarinal lymph
nodes, but no clinical evidence for distant metastasis is
found [1]. Radiochemotherapy is an integral component
of the multimodal treatment for these locally advanced
patients. Despite improvements in radiotherapy delivery,
different chemotherapy combination and schemes, the
median survival in this relatively heterogenous collective
population is ~ 21 months with 3 years survival rates
of ~ 30% [2–8].
The chromosomal rearrangement between ALK and
EML4 was first reported by Soda et al. from a resected
specimen of a male lung adenocarcinoma patient [9].
Between 3% to 7% of NSCL tumors harbor the EML4-
ALK fusion [10, 11]. It is predominantly detected in
adenocarcinomas of light smokers (< 10 packs per year)
or non-smokers at a younger age, and is independent of
epidermal growth factor receptor (EGFR) or KRAS
mutations [12]. The EML4-ALK fusion protein leads to
an aberrant activation of the ALK tyrosine kinase and
its related downstream signaling [13]. A number of
interconnected pathways are involved in ALK downstream
signaling among which the MAP Kinase pathways including
Ras- ERK and phosphoinositide 3-kinase (PI3K)-Akt are
best characterized [14]. Activation of ALK-mediated signal-
ing pathways plays a key role in tumorigenic transformation
of cells by promoting cell growth and inhibiting apoptosis,
irrespective of the originating organ [15, 16]. Soda et al.
have shown that cells overexpressing EML4-ALK are able
to generate subcutaneous or lung orthotopic tumors in
a nude mouse model [9, 17]. Another chromosomal
translocation between the nucleophosmin (NPM) gene
on chromosome 5q35 and ALK gene on 2p23 is
expressed in 60%–70% of anaplastic large cell lymphoma
(ALCLs) [13, 18, 19].
Based on the discoveries of ALK as an important
oncogene and the encoded fusion protein in development
of different cancers, a search for small molecular ALK-
tyrosine kinase inhibitors (TKIs) identified Crizotinib
(PF-02341066) as the first in class compound receiving
FDA-approval for treatment of ALK-positive advanced
lung cancer in 2011 [20]. However, Crizotinib was
originally identified in a screening program searching
for a c-Met receptor tyrosine kinase inhibitor (RTKi).
Accordingly, Crizotinib is not considered a specific ALK-
inhibitor (with a half maximal inhibitory concentration,
IC50: 24 nM) and more potently inhibits other kinases such
as c-Met (IC50: 11 nM) [21] and ROS1 (IC 50: 1.7 nM) [10].
Moreover, a gatekeeper mutation in the active kinase
domain (L1196 M) renders ALK-positive lung cancer
cells resistant to Crizotinib therapy [22]. In contrast,
ALK-positive NSCLC cells harboring this gatekeeper
mutation remain highly sensitive to second generation
ALK-inhibitors such as TAE684 [22, 23].
TAE684 is a potent and selective ALK-inhibitor with a
reported IC50 of ~ 3 nM in ALK positive cell lines [24]. It
was first reported to block the growth of ALCL-derived
and ALK-dependent cell lines with IC50 values between 2
and 10 nM [25]. The inhibitory effects were also observed
in NSCLC cell lines with IC50 values between 15 and
50 nM [23]. TAE684 was shown to induce apoptosis and
cell cycle arrest via rapid and sustained inhibition of
NPM-ALK phosphorylation and its downstream effectors
including ERK, Akt and STAT3 and/or STAT5b [25].
Currently, ALK-inhibitors are approved only for
advanced NSCLC. The translation of ALK-inhibitors
in locally advanced NSCLC patients with EML4-ALK
fusion will largely depend on a better understanding
of the effects elicited by this novel class of drugs in
combination with radiotherapy. Therefore, we aimed
to explore the interaction of radiotherapy and ALK-
inhibition by TAE684 in tumor cell lines with and
without ALK-fusion. This is, to our knowledge the
first report on beneficial effects of this combination in
ALK-positive tumors. It further supports the concept
of targeting oncogene addiction combined with radio-
therapy, preferably with carbon ions, investigated at
the German Research Foundation (DFG) “clinical research
group heavy ion therapy (KFO-214)” within the project
TP5 “Heavy Ions in Lung Cancer”.
Methods
Cells and cell culture
LLC cells were purchased from ATCC, Manassas, USA;
adenocarcinomic human alveolar basal epithelial (A549)
cells were obtained from Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH (DSMZ)
and the human NSCLC cell line H3122 was provided
by Frederick National Laboratory for Cancer Research,
Maryland, USA. A549 cells were cultured in Dulbecco’s
modified Eagle’s Medium (DMEM) (Biochrom) con-
taining 10% FBS as previously described [26]. LLC and
H3122 cells were cultured in RPMI1640 medium supple-
mented with 10% fetal bovine serum (FBS) (Biochrom). For
H3122, additional 1% L-glutamine (Sigma) was added. The
ALK-inhibitor TAE684, C30H40ClN7O3S, with molecular
weight 614.2017 [g/mol] was obtained from Absource
Diagnostics GmbH (Selleckchem) and dissolved in ethanol.
The 2D molecular structure and 3D conformer of TAE684
are adapted from PubChem (http://pubchem.ncbi.nlm.nih.
gov, PubChem id: 16038120) and provided in Fig. 1a.
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Fig. 1 (See legend on next page.)
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Cell proliferation assay
H3122, LLC, and A549 cells were seeded in 96 well
plates at 5000 cells/well. Cells were treated with TAE684
for 2 h before exposure to 4 Gy of irradiation. Cell conflu-
ence was monitored by time-lapse microscopy as previ-
ously described using IncuCyte ™ Zoom (Essen BioScience)
with a 10X objective for 72 h [27]. In addition, fluorimetric
measurement was performed using the CyQUANT® Direct
Cell Proliferation Assay (Life Technologies) according to
manufacturers’ instruction (3 Fountain Drive Inchinnan
Business Park, Paisley PA4 9RF, UK). In brief, cells pro-
liferation was quantified 72 h post treatment using 2X
detection reagent (11.7 mL PBS, 48 μL CyQUANT®
Direct nucleic acid stain and 240 μL CyQUANT® Direct
background suppressor I). Signal intensities after in-
corporation of fluorescent CyQuant dye were measured
at 485/520 nm filter set by Infinite M200 Microplate
reader (Tecan). The signal intensity from treated groups
was normalized to the one of vehicle groups.
Cell apoptosis assay
For time-lapse live microscopy of apoptosis, CellPlayer™
Kinetic Caspase-3/7 Assay (Essen BioScience) was used
to measure the activity of the executer Caspase 3/7 as
surrogate for apoptotic cell death. H3122 cells were
seeded in 96 well plates at 5000 cells/ well. Cells were
treated with 5 nM TAE684 for 2 h before exposure to
4 Gy of irradiation. DEVD-NucView™ 488 caspase-3
substrate (Biotium) was then added at a final concen-
tration of 5 μM, and cells were monitored for 72 h with
IncuCyte ™ Zoom using a 10X objective. At the end of
the monitoring period, Vybrant DyeCycle Green (Life
Technologies) diluted in PBS was added at a final concen-
tration of 1 μM to determine the total number of cell
nuclei (DNA-stain). Fluorescence was measured with exci-
tation at 480 nm and detection at 544 nm. The average
fluorescence signal per well was calculated as the total
fluoresce intensity per well divided by the corresponding
Vybrant DyeCycle Green signal intensity. The signal
intensity from treated groups was normalized to the vehicle
groups with or without irradiation, respectively.
Clonogenic assay
A pilot experiment was performed to determine the plating
efficacy for each cell type, i.e. detecting the number of col-
onies formed as the function of different cell densities.
Based on these data, 75 to 10,000 cells depending on
radiation dose was seeded in triplicate into T25 flasks
containing 5 mL medium overnight and exposed to
4 nM TAE684or vehicle (final ethanol concentration of
≤0.05%) for 2 h. The cells were then irradiated with
X-RAD 320 (Precision X-Ray; 320.0 keV/12.5 mA) at room
temperature at a dose range of 0, 1, 2 and 4 Gy. Carbon
irradiation was performed at the Heidelberg Ion Therapy
Center (HIT) with the horizontal beamline using a raster
scanning technique as described [28]. Cell monolayers
were irradiated with 0, 1, 2, 4 Gy physical dose which
were delivered as an extended SOPB of 10 mm at a
water equivalent depth of 120 mm. Cells were subse-
quently cultured at 37 °C/ 5% CO2 until colonies consisting
of at least 50 cells formed in the control culture (without
TAE684 or irradiation). The colonies were fixed with 75%
methanol and 25% acetic acid and stained with the 1 g/L
crystal violet.
Statistical data analysis
The kinase inhibition spectrum (IC50) of TAE684 was
visualized (Fig. 1a) and mapped by TREE spot™ Compound
Profile Visualization Tool (http://www.discoverx.com/
services/drug-discovery-development-services/treespot-
data-analysis) [25]. The number of colonies was quantified
with Image J software (http://rsbweb.nih.gov/ij) and the
survival fraction (SF) was estimated according to the
formula: SF = number of colonies formed in test condition/
(number of cells seeded × plating efficiency of control
group). The sensitizer enhancement ratio (SER) was
calculated as the surviving fraction in vehicle-treated cells
divided by that for TAE684-treated cells. Clonogenic
survival and SER were performed using the CS-Cal
(www.oncoexpress.de). Student’s t-test was utilized to
evaluate the significance between groups. P < 0.05 was
significant. Data represent mean ± standard deviation (SD)
if not otherwise indicated.
Results
Antiproliferative effects of TAE684 in NSCLC
To assess the effects of TAE684 on cell proliferation,
EML4-ALK fusion positive H3122 cells as well as A549
and LLC (both EML4-ALK negative) were treated with
TAE684 (0–100 nM) and relative proliferation was
determined 72 h post treatment using the Cyquant assay.
TAE684 potently inhibited H3122 cell proliferation with
an IC50 ~ 8.2 nM (Fig. 1b). In contrast, A549 cells showed
modest sensitivity with a U-shaped dose response and
(See figure on previous page.)
Fig. 1 Selective antiproliferative effect of TAE684 in ALK-positive NSCLC. The kinase inhibition profile by TAE684 (IC50, mapped by TREE spot) as
well as its 2D and 3D molecular structures (adapted from PubChem) are shown (a). Cell proliferation was assessed by counting viable cells 72 post
treatment with a cell-permeant DNA-binding fluorescent dye (CyQuant-Direct) (b). Alternatively, cell proliferation was monitored longitudinally by live
microscopy and the confluence levels as well as representative photomicrographs are presented (c and d). TAE684 potently inhibited cell proliferation in
ALK-positive H3122 NSCLC but was less or not effective in A549 and LLC cells, respectively. Bars represent mean ± SD. TK: tyrosine kinase; Ctrl: control
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~ 12% maximum inhibition at 40-50 nM (p < 0.05, Fig.
1b). LLC were resistant to TAE684 treatment in the
dose range studied (up to 100 nM). In line with these
observations, cell proliferation kinetic determined by
time- lapse microscopy in 3 h intervals for a period of
72 h post therapy revealed a similar sensitivity pattern.
A significant delay in H3122 cells was observed after
40 nM TAE684 treatment (p < 0.001, Fig. 1c and d). In
contrast, 40 nM TAE684 does not affect LLC growth
kinetic and elicited a moderate effect on A549 cells
with a late onset (p < 0.001 at 72 h) and 13% reduction
of cell confluence as compared to vehicle treated con-
trol (Fig. 1c and d). Together, these data confirm potent
and selective antiproliferative effects of TAE684 in ALK
positive NSCLC.
TAE684 only augments antiproliferative effects of
radiotherapy in ALK-positive NSCLC
To evaluate the effects of dual treatment with TAE684
and radiation on cell proliferation, H3122, A549 and
LLC cells were treated with TAE684 (40 nM) for 2 h
prior to irradiation (4 Gy). Cell confluence was mea-
sured 72 h post treatment by microscopy. Radiotherapy
exhibited a modest but significant inhibition of cell
proliferation in H3122 (15% inhibition, p < 0.05, Fig. 2a),
LLC cells (16% inhibition, p < 0.01, Fig. 2b) and A549
cells (13% inhibition, p < 0.05, Fig. 2c). Combined
treatment with TAE684 and radiotherapy significantly
reduced cell proliferation as compared to radiotherapy
alone (56%, p < 0.01, Fig. 2a) but only in ALK-positive
H3122 cells. In contrast, the same response was achieved
Ctrl TAE684
0Gy
4Gy
72 h 300 µM
Ctrl TAE684
0Gy
4Gy
36 h
Ctrl TAE684
0Gy
4Gy
72 h
A
C
B
0
20
40
60
80
100
120
0 4
re
b
m
u
nllec
dezila
mr
o
N
Dose [Gy]
H3122 0 nM
40 nM
*
**
**
**
0
20
40
60
80
100
120
0 4
re
b
m
u
nllec
dezila
mr
o
N
Dose [Gy]
LLC 0 nM
40 nM
** **
0
20
40
60
80
100
120
0 4
re
b
m
u
nllec
dezila
mr
o
N
Dose [Gy]
A549 0 nM
40  nM
*
Fig. 2 TAE684 selectively augments radiotherapy-induced antiproliferative effects in ALK positive NSCLC. Cell proliferation after incubation with
vehicle or TAE684 (40 nM) alone or in combination with irradiation (4 Gy) was evaluated in H3122 (a), LLC (b) and A549 (c) cells (left panel). Only
in ALK-positive H3122 cells dual treatment with TAE684 and radiotherapy reduced cell proliferation by 56% as compared to radiotherapy alone
(p < 0.01). Photomircographs of representative fields after 72 h (H3122 and A549) or 36 h (LLC) are shown on the right panel. Cell numbers were
normalized to that of non-treated groups for each cell line. Bars indicate mean ± SD. * p < 0.05 and ** p < 0.01
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by dual therapy in LLC cells (Fig. 2b) while the dual
combination was less efficient in inhibiting cell prolifera-
tion in A549 cells as compared to radiotherapy alone
(Fig. 2c). Representative photomicrographs showing the
NSCLC cell confluence levels at 72 h (H3122 and A549)
or 36 h (LLC) post therapy are presented.
Synergistic effects of combined TAE684 & radiotherapy
on NSCLC survival
To further evaluate the effects of mono- and dual ther-
apies, the clonogenic survival of all three NSCLC lines
was assessed. The SF of ALK-positive H3122 cells was
prominently reduced with SF~61% at 4 nM TAE684.
Interestingly, a SF ~23% was achieved at 4 nM TAE684
in LLC cells that were otherwise found to be resistant in
proliferation assay. At this dose level, the clonogenic
survival of A549 cells was not affected (Fig. 3a). Compara-
tive analysis across all three cell lines was performed using
4 nM TAE684 and a dose series of radiotherapy (0–4 Gy).
The most significant radiosensitizing effect of TAE684
was found in the ALK-positive H3122 cells (Fig. 3c) with
SER: 1.6 (p < 0.01) at SF50%. In LLC cells (Fig. 3d),
TAE648 exerted a radioprotective effect. The protection
enhancement ratio (PER) was 1.5 (p < 0.01) at SF 50% for
combined treatment with TAE684 and irradiation vs.
irradiation alone. TAE684 moderately sensitized A549 cells
to irradiation with SER: 1.23 (p = 0.03, at SF50%) (Fig. 3e).
TAE684 enhanced radiation induce apoptosis in H3122 cells
In order to understand the basis of reduced cell viability
in the presence of TAE684 and/or irradiation, caspases
3/7 was examined as a marker of apoptosis. TAE684
alone induced 14% apoptosis compared to vehicle con-
trol in ALK-positive H3122 cells (Fig. 3b). Likewise, in
irradiated groups, TAE684 enhanced caspase-3 activity
by 41% as compared to the vehicle groups. Addition of
4Gy radiotherapy led to ~ 3-fold enhancement compared
to TAE684 monotherapy in apoptotic activity (p < 0.05).
Together, these data support potent radiosensitizing
effects of TAE684 in ALK-positive H3122 NSCLC.
TAE684 sensitizes ALK-positive NSCLC to carbon ions
Next, we sought to investigate the effect of ALK-
inhibition in combination with high linear energy trans-
fer (LET) particle therapy using carbon ions. Clonogenic
survival of all three NSCLC lines was determined at 0
and 4 nM TAE684 and 0, 1, 2 and 4 Gy irradiation with
carbon ions. TAE684 significantly sensitized ALK-positive
H3122 to carbon irradiation with SER: 1.61 (p < 0.05 at SF
50%) (Fig. 4a). A moderate enhancement of carbon ions
was observed in LLC with SER: 1.27 (p < 0.05 at SF50%)
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apoptosis in H3122 cells and the addition of radiotherapy enhanced Caspase 3/7 level in a synergistic manner (b). H3122 (c), LLC (d) and A549 (e) cells
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a trend toward antagonistic effects was found in LLC cells treated with this dual combination. Bar represent mean ± SD
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(Fig. 4b). Addition of TAE684 does not sensitize A549
cells (SER: 1.03, p > 0.05, at SF50%) (Fig. 4c). Together
these data support beneficial effects of combined carbon
ion therapy and TAE684 in ALK-positive NSCLC.
Discussion
Here we report on beneficial effects of combined ALK-
inhibition and radiotherapy in NSCLC with EML4-ALK-
fusion leading to a constitutive activation of ALK-signaling.
Inhibition of ALK-signaling by TAE684 potently and
selectively augmented antiproliferative and pro-apoptotic
effects of irradiation in ALK-positive tumors. This com-
bination further elicited synergistic effects in reducing the
clonogenic survival of ALK-positive H3122 cells. In
contrast to ALK-positive H3122 tumor cells, addition
of TAE684 does not affect the antiproliferative effect of
radiotherapy in two other NSCLC lacking ALK-activation.
While the clonogenic survival was moderately reduced by
addition of TAE684 to radiotherapy in A549 cells, TAE684
exerted a radioprotective effect in LLC cells as shown by
clonogenic survival assays. This data suggests a narrowed
indication for combined radiotherapy and ALK-inhibition
only in NSCL tumors with aberrant ALK-activation. In
contrast to conventional x-ray irradiation, TAE684 moder-
ately sensitized LLC cells (SER: 1.27) when combined with
carbon ion irradiation. Hence, radiation quality specific
differences may exist in NSCLC response to ALK-
inhibitors that warrants further investigation. This is in
line with recently reported data on differential phos-
phoproteome response of NSCLC cells to conventional
radiotherapy vs. proton and carbon irradiation [29].
Together with data of enhanced eradication of otherwise
radioresistant tumor stem cells by carbon ions, these data
indicate further exploration of distinct radiobiological
features of different radiation qualities [30]. The potent
sensitizing effects of TAE684 on carbon ions observed in
ALK-positive H3122 cells (SER: 1.61) suggest further
evaluation of this combination in the emerging field of
high-LET particle therapy. These data are in complete
alignment we recently reported data for combined crizo-
tinib and radiotherapy in NSCLC based on tumor ALK
status as schematically summarized in Fig. 5 [30].
High-precision irradiation with carbon ions has shown
promising clinical outcomes in NSCLC [31, 32]. Addition
of ALK-inhibitors in ALK-positive NSCLC may therefore
augment local control effects of radiotherapy and in parallel
provide a systemic therapy option to prevent distant tumor
growth as the key pattern of therapy failure. Promising data
on beneficial effects of combined ALK-inhibition and
carbon ion irradiation reported in this study suggest
further validation of this concept in preclinical in-vivo
tumor models.
TAE684 is a potent small-molecule inhibitor of ALK
activity that was shown to block the growth of ALK-
dependent cells [25]. In contrast to the FDA/EMA
approved, less specific ALK-inhibitor Crizotinib, the
selectivity of TAE684 for ALK inhibition was demon-
strated across a panel of 22 Kinases and between 100
to 1000 fold higher concentrations of TAE684 was
required to inhibit other tyrosine kinases [25]. It was
initially identified to inhibit proliferation of ALCLs
that harbor the t (2; 5) (p23; q35) chromosomal trans-
location between ALK and NPM. NPM-ALK is a potent
oncogene, possessing strong transforming ability in a wide
array of different cell types in vitro and hematopoietic
cell lines such as the myeloid line 32Dcl3 [33]. The
80-kD fusion protein is an oncogenic tyrosine kinase
that activates downstream signaling pathways related
to mitogenic, antiapoptotic and possibly DNA repair
capabilities such as PI3K-Akt and JAK-STAT pathways
[34–38]. Further studies are needed to identify the
relevance of different proposed ALK-downstream signaling
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Fig. 4 TAE684 sensitizes ALK positive NSCLC cells to carbon ions. The surviving fraction of H3122(a), LLC (b) and A549 (c) cells was determined after
vehicle or TAE684 (4 nM) treatment and carbon ion irradiation (0, 1, 2 or 4 Gy). TAE684 treatment potently sensitized ALK-positive H3122 to carbon ion
radiotherapy, while a moderate radiosensitivity was induced in LLC cells and no response was observed in A549 cells. Bars indicate mean ± SD
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pathways in the radiosensitizing effects of TAE684
reported here.
NSCLC is one of the most challenging malignancies,
although its prognosis has improved due to new thera-
peutic agents and better combined therapy regimens.
The introduction of FDG-PET-CT has reduced the number
of falsely classified locally advanced patients and together
with improved target volume delineation and radiotherapy
techniques contributed to a better patient outcome.
Despite all these progresses, long-term survival is still
limited in patients presenting at locally advanced or
metastatic stages. Thus, personalized therapies based
on individual tumor characteristics are urgently needed
for NSCLC patients. The development of ALK inhibi-
tors has provided a promising therapeutic opportunity
for treatment of advanced metastatic NSCLC [39, 40].
Based on our data, a relatively large fraction of patients
with locally advanced disease and ALK-positive tumors
may benefit from combined ALK inhibition and radio-
therapy. Hence, in addition to the current practice in
stage IV disease, routine examination of ALK status
might be warranted in locally advanced Stage III NSCLC
prior to radiotherapy. In analogy to combined EGFR-
inhibition (cetuximab) and radiotherapy in HNSCC, it is
conceivable that ALK-inhibition may provide a less toxic
alternative to chemotherapy for concurrent treatment
of ALK-positive NSCLC with radiotherapy [41]. Our
data unequivocally indicate further in-vivo and clinical
exploration of this favorable combination in ALK-fusion-
harboring NSCLC.
Conclusions
In this report, we demonstrated that concurrent inhibition
of ALK in combination with irradiation reduced the
proliferative capacity and enhanced apoptosis selectively
in human H3122 NSCLC tumors with EML4-ALK trans-
location. Based on the clonogenic survival data, a syner-
gistic activity was further observed between irradiation
and TAE684 treatment in H3122 cells. ALK-inhibition
further sensitized NSCLC cells to particle therapy with
carbon ions. To our knowledge, this is the first demon-
stration of potent radiosensitizing effects of TAE684 in
NSCLC cells harboring EML4-ALK fusion gene. This
study constitutes a critical step towards clinical translation
of this favorable combination in NSCLC.
Combined Radiotherapy and Targeting of EML4-ALK Oncogene Addiction Exemplified by Crizotinib
Selective in-vivo and in-vitro radiosensitization
of Alk addicted NSCLC
ALK activation via Translocation
Fig. 5 Selective radiosensitization of EML4-ALK oncogene addicted tumors exemplified by crizotinib. A schematic overview of another study conducted
in frame of the KFO-214 evaluating the impact of the first generation ALK inhibitor crizotinib on tumor response to radiotherapy [30]. Different tumor cell
lines were profiled for their addiction to ALK signaling by western (ALK activation) and FISH (ALK translocation). Crizotinib was originally intended to
target cMET, hence cMET signaling was also investigated in all evaluated cell lines. Comprehensive in-vivo tumor growth delay studies revealed selective
radiosensitzation of ALK addicted NSCLC cell lines. This was in line with synergistic effects of dual combination observed after photon orcarbon
irradiation, respectively, by clonogenic survival assay and isobologram analysis. Together with data reported on second-generation ALK inhibitor TAE684
here, our data support the combination of this class of agents with radiotherapy in ALK addicted NSCLC
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